Humana Inc. (NYSE:HUM) Receives Consensus Rating of “Hold” from Analysts

Humana Inc. (NYSE:HUM) has been assigned a consensus recommendation of “Hold” from the twenty-five brokerages that are currently covering the stock, Marketbeat Ratings reports. Nineteen equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $300.50.

Several research firms have recently issued reports on HUM. TD Cowen upped their target price on shares of Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Piper Sandler downgraded shares of Humana from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $392.00 to $274.00 in a research report on Thursday, October 3rd. Stephens reiterated an “equal weight” rating and issued a $250.00 price objective on shares of Humana in a research note on Wednesday, October 9th. Cantor Fitzgerald restated a “neutral” rating and issued a $395.00 target price on shares of Humana in a research note on Tuesday, October 1st. Finally, Morgan Stanley increased their price target on Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research report on Tuesday.

Institutional Investors Weigh In On Humana

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Financial Designs Inc. ADV boosted its holdings in shares of Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 61 shares during the period. CarsonAllaria Wealth Management Ltd. boosted its stake in Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after purchasing an additional 39 shares during the period. Atwood & Palmer Inc. purchased a new position in Humana during the 3rd quarter valued at about $29,000. Ashton Thomas Securities LLC bought a new stake in shares of Humana during the third quarter valued at about $31,000. Finally, Your Advocates Ltd. LLP increased its position in shares of Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

HUM stock opened at $233.89 on Wednesday. The company has a market capitalization of $28.16 billion, a P/E ratio of 20.72, a price-to-earnings-growth ratio of 2.15 and a beta of 0.53. Humana has a 52-week low of $213.31 and a 52-week high of $475.00. The business has a 50-day simple moving average of $274.43 and a two-hundred day simple moving average of $322.89. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The company had revenue of $29.30 billion for the quarter, compared to analysts’ expectations of $28.66 billion. Research analysts expect that Humana will post 16.14 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.51%. The ex-dividend date is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is presently 31.36%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.